

## Supplementary material

*Hoppe A, Wojtasińska E, Rupa-Matysek J. Impact of neutrophil extracellular trap formation on thromboembolic events and prognosis in patients with newly-diagnosed lymphoproliferative disorders. Pol Arch Intern Med. 2024; 134: 16648. doi:10.20452/pamw.16648*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Table S1.** Baseline patients' characteristics and comparisons in the groups with/without VTE

Parameter	VTE n=9	Non-VTE n=56	p – value
	Me (Q <sub>1</sub> –Q <sub>3</sub> ) or % (n)		
Age at diagnosis, years	61.6 (56.1-70.8)	59.2 (45.9-66.65)	0.30
Gender, male	44% (4)	51.8% (29)	0.74
CCI ≥3	0% (0)	5.4% (3)	0.10
Body weight, kg	61 (51.4-80)	71 (62-79)	0.30
Height, cm	170.1 (161.5-174)	168 (162-176)	0.69
BMI, kg/m <sup>2</sup>	22.2 (19.3-26.2)	24.9 (21.3-28.2)	0.15
WBC, G/l	7.7 (5.8-10.8)	6.6 (4.7-8.6)	0.26
LYMPH, G/l	1.2 (1-1.9)	1.5 (1.1-2.06)	0.60
HGB, g/dl	10.2(9-12.6)	12.3 (10.2-13.4)	0.17
PLT, G/l	358 (266.5-414)	260 (207-333)	0.04
APTT, s	32.8 (30.9-33.7)	30 (26.5-32.45)	0.07
PT, s	13.6 (12.9-13.7)	12.7 (11.8-13.4)	0.21
D-Dimer, µg/l	1819 (1450-2352)	762 (276-1802)	0.15
CRP, mg/l	10 (4-32)	4 (4-16)	0.55
Albumin, g/l	32.5 (30-35.5)	36 (31-38)	0.31

LDH, IU/l	188.5 (149-467)	203 (174-270)	0.90
Serum creatinine, $\mu\text{mol/l}$	80 (78.5-96.5)	73 (57-96)	0.22
CH3, Pg/ml	889.8 (680.6-1674.7)	950.6 (730.9-2028.1)	0.72
OS, months	26.4 (19.8-31.5)	24.4 (16.9-28.3)	0.28
Time to relapse, months	11.1 (3.5-21.9)	11.4 (3.5-35.8)	0.99

Abbreviations: APTT – activated partial thromboplastin time; BMI – body mass index; CCI - Charlson comorbidity index; CH3 – citrullinated histone H3; CRP – C-reactive protein; HGB – hemoglobin; LDH – lactate dehydrogenase; LYMPH – absolute lymphocyte count; OS – overall survival; PLT – platelets; PT – prothrombin time; VTE – venous thromboembolic event; WBC – white blood cells

**Table S2.** VTE risk assessment scores and prophylaxis in the groups with/or without VTE.

	Parameter	All	VTE	Non-VTE	p – value
		% (n)			
Myeloma		n=35	n=7	n=28	
	Khorana score High risk ( $\geq 3$ pts)	25.7% (9)	57.1% (4)	17.9% (5)	0.1
	IMPEDE-VTE High risk ( $\geq 4$ pts)	74.3% (26)	100% (7)	67.9% (19)	0.21
	SAVED SCORE High risk ( $\geq 2$ pts)	14.3% (5)	14.3% (1)	14.3% (4)	0.57
	Prophylaxis - Yes	97.1% (34)	100% (7)	96.4% (27)	0.46
	Prophylaxis type - ASA - LMWH	32.4% (11) 67.6% (23)	57.1% (4) 42.9% (3)	25.9% (7) 74.1% (20)	0.20
Lymphoma		n=30	n=2	n=28	
	Khorana score High risk ( $\geq 3$ pts)	16.7% (5)	0% (0)	17.9% (5)	0.74
	Prophylaxis - Yes	66.7% (20)	100% (2)	64.4% (18)	0.67
	Prophylaxis type - LMWH - DOACs	95% (19) 5% (1)	100% (2) 0% (0)	85% (17) 5.5% (1)	0.17

Abbreviations: ASA – acetylsalicylic acid; DOACs – direct oral anticoagulants; LMWH – low-molecular-weight heparin; VTE – venous thromboembolic event